<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773058</url>
  </required_header>
  <id_info>
    <org_study_id>QHB-YY 2008</org_study_id>
    <nct_id>NCT00773058</nct_id>
  </id_info>
  <brief_title>Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS)</brief_title>
  <official_title>Effect of Treatment With Stress-Doses Glucocorticoid on Mortality in Patients With ARDS and Relative Adrenal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if stress doses of hydrocortisone improve early outcome
      in patients who are in early stage of ARDS and with relative adrenal insufficiency.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of clinically definite ARDS confirmed by AECC criteria in 1994</measure>
    <time_frame>within the first 3 days after surgery onset of ARDS</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>glucocorticoid+RAI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>stress-dose glucocorticoid treatment, compared to placebo group and ACTH test hints RAI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + RAI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no glucocorticoid But ATCH test hints RAI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glucocorticoid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>stress-dose glucocorticoid treatment, compared to placebo group and ACTH test does not hint RAI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no glucocorticoid But ATCH test does not hint RAI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocortisone</intervention_name>
    <description>hydrocortisone 100mg q8h</description>
    <arm_group_label>glucocorticoid+RAI</arm_group_label>
    <arm_group_label>glucocorticoid</arm_group_label>
    <other_name>glucocorticoid</other_name>
    <other_name>cortical hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>normal saline 100ml q8h</description>
    <arm_group_label>placebo + RAI</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  within the first 3 days of onset of clinically definite ARDS confirmed by AECC
             criteria in 1994

          -  18 to 85 year old

        Exclusion Criteria:

          -  pregnancy or lactation

          -  tumor or other immunologic disease

          -  immunosuppressive drug used

          -  bone marrow or lung transplantation

          -  primary or secondary disease of adrenal gland

          -  hormone used within 3 months

          -  refusing conventional therapy

          -  be in other clinical tests within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>February 17, 2009</last_update_submitted>
  <last_update_submitted_qc>February 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. QIU Hai-bo</name_title>
    <organization>Chinese Medical Association</organization>
  </responsible_party>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>glucocorticoid</keyword>
  <keyword>adrenal insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 29, 2011</submitted>
    <returned>October 3, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

